The text starts here.

News Release

Information in the news releases is current on the date of the announcement, but is subject to change without prior notice.

2004 Release

December 17, 2004 Eisai Recieves A Positive Opinion for Zonegran(R) Marketing Authorization From European Committee For Medicinal Products for Human Use (CHMP)
November 19, 2004 Notice Concerning Completion of the Acquisition of the Company's Own Shares through ToSTNeT-2
November 18, 2004 Notice Concerning the Acquisition of the Company's Own Shares through ToSTNeT-2
November 15, 2004 Eisai In-licenses Anti-hepatitis B Agent clevudine From Bukwang Pharm (South Korea)
October 29, 2004 Eisai Reacquires Worldwide Rights for a Triazole-Type Anti-Fungal Agent
October 29, 2004 Eisai Announces Establishment of its Pharmaceuticals Marketing Subsidiary in India
October 28, 2004 Eisai Announces Establishment of its European Regional Headquarters (Holding Company) in the U.K.
October 22, 2004 Eisai Receives Approvals for New Formulations of ARICEPT (R) (donepezil hydrochloride), Orally Disintegrating Tablet and Liquid Formulation in the U.S.
August 27, 2004 Notice Concerning the Revision of Eisai Co., Ltd. and Consolidated Subsidiaries Quarterly Financial Report for the Period Ended June 30, 2004
August 5, 2004 Eisai Launches SAHNE WHITE R, A Medicated Skin Cream that Provides Protection Against Spots and Produces Smooth Skin
July 30, 2004 Eisai's German Pharmaceuticals Marketing Subsidiary Starts Promotion of AstraZeneca's ENTOCORT R, a locally acting Glucocorticosteroid for Inflammatory Bowel Diseases
July 30, 2004 Notice Concerning Acquisition of the Company's Own Shares
July 8, 2004 Eisai Receives European Marketing Authorization for PARIET R(rabeprazole sodium) for Zollinger-Ellison Syndrome
July 1, 2004 Notice Concerning Stock Options (Stock Acquisition Rights) Including the Amount Paid In Upon the Exercise of Stock Options
June 30, 2004 Eisai Launches the First Treatment in Japan for Apnea of Prematurity Low Concentration Aminophylline, APNISSION R Injection 15mg
June 28, 2004 Eisai's Statement to AD2000 Clinical Trial Led By the Collaborative Group of University of Birmingham
June 28, 2004 Eisai Launches New Formulation of ARICEPT R, Rapid Disintegration Tablet, in Japan
June 24, 2004 Notice on Allotment of Stock Options (Stock Acquisition Rights)
June 18, 2004 Sanko Junyaku Co., Ltd., Subsidiary of Eisai Co., Ltd., to Launch New DCP Diagnostic Test Kit for Hepatocellular Carcinoma (HCC), LUMIPULSE PIVKA-II EISAI
May 31, 2004 Eisai Submits MAA for New Formulation of ARICEPT R (donepezil hydrochloride), Liquid Formulation in the European Union
May 12, 2004 Eisai Launches SACLON (R) & SACLON (R) Tablets with Increased Ingredients for Restoration of Damaged Stomach Mucosa and Acid Neutralization
May 11, 2004 Notice on Providing Stock Options in the Form of New Stock Issuance
May 11, 2004 Notice Concerning the Spin off of the Machinery Division of Eisai Co., Ltd
May 7, 2004 Amendment of the Co-Development, Licensing and Supply Agreement for the Obesity Management Agent KES524
April 23, 2004 ARICEPT (R) Application for Vascular Dementia is Withdrawn in the European Union
April 21, 2004 PARIET (R) (rabeprazole sodium) Approved for On-Demand Therapy of Symptomatic GORD in the European Union
April 19, 2004 Eisai Launches MENTEC(R) HERB for Irritation-Associated Fatigue and Headache
April 2, 2004 Eisai's German Pharmaceuticals Marketing Subsidiary and GlaxoSmithKline Sign a Promotion Agreement for IMUREK(R), an Immunosuppressant
March 31, 2004 Eisai acquires anti-epileptic drug Zonegran(R) (zonisamide) from Elan in North America and Europe
March 1, 2004 Eisai Launches CHOCOLA(R) BB DRINK II, A New Vitamin B2 Drink for Alleviation of Skin Roughness
February 25, 2004 Announcement on the Adoption of "Company with Committees System"
February 25, 2004 Integration and Reorganization of Eisai's Machinery Operations
February 10, 2004 E2000, Transdermal Muscle Relaxant Application Withdrawn in Japan
February 9, 2004 Eisai Announces In-Licensing Agreement with Novartis for Rufinamide, A New Antiepileptic Agent
February 3, 2004 Notice Concerning Completion of the Acquisition of the Company's Own Shares through ToSTNeT-2
February 2, 2004 Notice Concerning the Acquisition of the Company's Own Shares through ToSTNeT-2
January 30, 2004 Eisai Commences Another US Legal Action Over Aciphex(R) ANDA Filing
January 15, 2004 Eisai Launches JUSTAT (R) Family of Products, Athlete's Foot and Ringworm Treatments
January 7, 2004 Eisai Inc., a U.S. Subsidiary of Eisai Co., Ltd., Assumes All Distribution Responsibilities for ACIPHEX (R)

Back to Top